Challenges With Commonly Available Dopamine Agonists in Parkinson's Disease

This section focuses on the side effects and clinical considerations associated with currently available dopamine agonists used to treat Parkinson’s disease. The speaker describes common adverse effects such as impulse control disorders, including compulsive gambling, hypersexuality, overeating, and excessive shopping, which are linked to D3 receptor stimulation and can occur in patients when combined with levodopa. Additional side effects include excessive daytime sleepiness, sleep attacks, and peripheral edema, highlighting the importance of careful patient counseling and monitoring, including involvement of family members. Due to these risks, the use of dopamine agonists has declined over the past decade, particularly as levodopa has demonstrated stronger efficacy in key clinical trials. The discussion concludes with optimism about newer, third-generation dopamine agonists under investigation that may offer improved efficacy with fewer adverse effects compared with earlier generations.